Access to Medicine Index homepage
New analysis: Handful of new children’s meds on the horizon. But will they be accessible to children in LMICs?
R&D for COVID-19 has increased, yet other pandemic risks go unaddressed
Despite years of warnings that novel coronaviruses were among the pathogens most likely to cause a global health emergency, the pharmaceutical industry, as well as society at large, was ill-prepared for the COVID-19 pandemic.
Less than half of key products are covered by access strategies in poorer countries
Low-income countries are most consistently overlooked when pharma companies apply equitable pricing, voluntary licensing and donations initiatives. Many products analysed are not covered by access strategies in any out of 106 countries.
News related to the Access to Medicine Index
"There have been massive improvements in global health in the past decades, with all major pharmaceutical companies taking action. To close the gaps that remain, a greater diversity of companies must get involved and stay engaged."
Jayasree K. Iyer
Executive Director Access to Medicine Foundation